Clinical trial · Interventional
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
A Multi-center, Randomized, Pilot Trial to Evaluate the My Hematology Oncology Patient Experience (MYHOPE™) for Multiple Myeloma (MM) Digital Care Network in Patients With MM
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study faced multiple challenges and its launch was heavily impacted by COVID, which in turn has significantly impacted the deployment and adoption goals for a digital technology pilot. These factors led to the difficult decision to close the study.
Summary
Brief summary (as posted)
NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM. The MyHOPE for MM Platform is a validated investigational device manufactured by Amalgam Rx, Inc. and designed to provide patients with a comprehensive set of tools and resources to support the patient throughout their overall experience with MM.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MyHope HCP Portal | Device | — | UNRESOLVED |
| MyHOPE™ for Multiple Myeloma | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Patient App + HCP Portal (Cohort 1)
- description
- Cohort 1 is to assess how patients will use the Patient App if connected in real time with the Healthcare professional (HCP) Portal
- interventionNames
- Device: MyHOPE™ for Multiple Myeloma
- Device: MyHope HCP Portal
- type
- EXPERIMENTAL
- label
- Patient App Alone (Cohort 2)
- description
- Cohort 2 is to assess how patients will use the Patient App where there is no connectivity to the Healthcare professional (HCP) Portal and thus no real-time data sharing with the HCP Portal
- interventionNames
- Device: MyHOPE™ for Multiple Myeloma
Primary outcomes (7)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is ≥ 18 years old with a diagnosis of Multiple Myeloma * Patient must reside in the USA. * Patients within each of the following subgroups, at one of the following timepoints, will be eligible for entry: 1. Newly-diagnosed multiple myeloma transplant-eligible 2. Patients undergoing their first ASCT 3. Newly-diagnosed multiple myeloma transplant-ineligible 4. Relapsed and/or refractory. Exclusion Criteria: * Patient has a condition(s) that, in the opinion of the Investigator, would make participation infeasible such as inability to provide informed consent, illiteracy, or inability to speak, read, and write in English. * Patient is on hospice. * Patient is receiving or has received an investigational agent \< 28 days prior to randomization or during this pilot study.
References
Publications (0)
Data not yet available